Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies

Background and Aims: Early biologic therapy treatment has demonstrated better outcomes in Crohn’s disease (CD). We evaluated the impact of CD duration in patients with moderately to severely active CD treated with risankizumab therapy. Methods: This post hoc analysis evaluated clinical, endoscopic,...

Descripción completa

Detalles Bibliográficos

Autores principales:	Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, Marc Ferrante, Satoshi Motoya, Remo Panaccione, Joana Torres, Ryan C. Ungaro, Kristina Kligys, Jasmina Kalabic, Javier Zambrano, Yafei Zhang, Geert D'Haens
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2024-01-01
Colección:	Gastro Hep Advances
Materias:	Biologics Crohn’s Disease Disease Duration Interleukin 23 Risankizumab
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2772572324000293
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!